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  Objectives      To identify predictors of clinical remission 
as well as of no x-ray progression in a cohort of early 
rheumatoid arthritis (ERA) treated with a tight-control 
protocol.  
  Methods      A total of 121 consecutive patients with 
ERA were treated to reach European League Against 
Rheumatism (EULAR) and/or American College of 
Rheumatology (ACR) clinical remission with methotrexate 
(MTX) for 3 months, then with a combination with anti-
tumour necrosis factor if the patient did not achieve a 
44-joint Disease Activity Score (DAS44) ≤2.4. At baseline 
and after 12 months all the patients had hand and foot 
joint radiographs. Very early rheumatoid arthritis (VERA) 
was deﬁ  ned as a disease with symptoms of less than 
12 weeks.   
  Results      In all, 46.3% of the patients reached DAS 
remission and 24.8% achieved ACR remission. More 
than 60% of patients reached remission with MTX. Male 
sex and an erythrocyte sedimentation rate <35 mm/h 
at onset arose as signiﬁ  cant predictors of EULAR 
remission, while VERA disease was the only predictor of 
ACR remission. At baseline, 28.1% of the patients were 
erosive. Multivariate analysis demonstrated that the only 
independent predictor of erosiveness was ‘not having 
VERA disease’. After 12 months, VERA was the only 
factor predicting a lack of new erosions.   
  Conclusions      VERA represents the best therapeutic 
opportunity in clinical practice to achieve a complete 
remission and to stop the erosive course of 
rheumatoid  arthritis.      
  INTRODUCTION 
  One of the most interesting ﬁ  ndings obtained in 
early rheumatoid arthritis (ERA) trials (ie, the BeST   
trial) has been the disappearance of any predictor of 
remission in patients treated ab initio with metho-
trexate (MTX) plus anti-tumour necrosis factor α 
(TNFα).  1   However, in the MTX-treated arms of 
trials, disease duration, disease activity and Health 
Assessment Questionnaire (HAQ) disability scores 
at baseline were best predictors of a good European 
League Against Rheumatism (EULAR) response.  2     3   
  In patients under TNFα blockade treatment, the 
percentage of patients reaching clinical remission is 
high, but the percentage of patients demonstrating 
no radiographic progression is even higher, whereas 
in patients treated with conventional disease-
  modifying antirheumatic drugs (DMARDs), clinical 
remission can also be observed in a high percentage 
of patients but x-ray progression appears to be less 
favourable.  1     4    –    6   
  When the concept of a very early treatment was 
introduced, even with DMARDs, a disease dura-
tion of less than 4 months emerged as a predictor 
of remission in ERA.  7    –    9   
  In this study we focused our attention on pos-
sible predictors, either in terms of clinical remis-
sion as well as in terms of x-ray remission (or lack 
of progression), in a cohort of ERA prospectively 
treated according to a very strict protocol.   
  PATIENTS  AND  METHODS 
  The study included 121 consecutive patients with 
ERA (disease duration <12 months) fulﬁ  lling the 
1987 and 2010 American College of Rheumatology 
(ACR) criteria for RA  10   who were attending our 
early arthritis clinic and that reached a follow-up 
of 12 months. All patients gave their informed con-
sent to enter into the study, which was approved 
by our Ethics Institutional Committee. 
  The disease duration was considered from the 
onset of the symptoms to baseline that corre-
sponded with the point of diagnosis and with the 
start of treatment. When disease duration was less 
than 3 months, patients were deﬁ  ned  as    having 
‘very early rheumatoid arthritis’ (VERA). In our 
cohort 44 patients (36.4%) had VERA (supplemen-
tary table 1). 
  The visits were performed every month up to 
3 months and every 3 months thereafter, and at 
each visit all clinical (Disease Activity Score (DAS), 
HAQ, joint count), immunological (rheumatoid fac-
tor (RF)-IgA, RF-IgM, anti-cyclic citrullinated peptide 
antibodies (ACPA) and anti-mutated citrullinated 
vimentin antibodies) and laboratory (  erythrocyte 
sedimentation rate (ESR), C reactive protein) data 
were registered. (For more details on patient char-
acteristics, treatment and follow-up see supplemen-
tary data ﬁ  le and supplementary table 1). 
  At the ﬁ  rst visit, once the diagnosis was con-
ﬁ  rmed, patients began taking MTX (up to 20 mg 
weekly) and when necessary a low dosage steroid. 
Patients were evaluated at each control visit and 
a combination treatment with anti-TNF (adali-
mumab 40 mg/every 2 weeks or etanercept 50 mg/
week) was begun if patients did not achieve a low 
DAS44 (≤2.4). At month 12, 73 patients (60.3%) 
were in monotherapy with MTX, while 20 patients 
(16.5%) were receiving an association with adali-
mumab and 28 patients (23.2%) an association 
with etanercept. 
  A patient was considered in clinical DAS44 remis-
sion if he/she reached a DAS value of <1.6  11   for at 
least two consecutive visits 3 months apart, and if 
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they also had no disease ﬂ  are within the previous 6 months, 
stable treatment for 6 months and no clinical indication for a 
change of treatment. 
  Besides EULAR remission, in order to deﬁ  ne whether stricter 
criteria could reﬂ   ect a better concordance between clinical 
involvement and radiological damage, we also assessed a sus-
tained ACR remission deﬁ  ned as fulﬁ  lling ﬁ  ve of the ACR remis-
sion criteria for two consecutive visits.  12   
  All the patients had hand and foot radiographs taken at base-
line and after 12 months of treatment. Radiographs were scored 
according either to Larsen score  13   or using the Sharp/van der 
Heijde  14   method, but in this case considering only the erosion 
score. Patients presenting a new erosion or the worsening of 1 or 
more points of Larsen and/or Sharp/van der Heijde erosion score 
were considered as radiological progressors.   
  RESULTS 
  After 12 months of treatment, 56 patients (46.3%) reached 
DAS remission (DAS44<1.6) (  table 1  ) and 26 more patients had 
reached a low disease activity (DAS44≤2.4). According to the 
ACR criteria, 30 patients (24.8%) reached remission (  table 2  ). 
A total of 91 patients (75.2%) reached a HAQ score of ≤0.5. 
Patients that did not reach DAS remission presented at base-
line a higher ESR (42.0±24.0 mm/h), DAS (3.6±0.7) and HAQ 
(1.4±0.7) with respect to patients that reached DAS remis-
sion (ESR 31.6±25.0 mm/h, p=0.01; DAS 3.0±0.8, p<0.0001; 
HAQ 1.1±0.7, p=0.04; respectively). Thus, patients with a high 
ESR, DAS and HAQ less frequently reached DAS remission 
(  table 1  ).   
  At the 12-month follow-up 60.3% of patients were receiving 
only MTX, and 39.7% were receiving MTX and anti-TNFα. 
  We observed a highly signiﬁ  cant fall of RF-IgM, of RF-IgA and 
a smaller decrease of ACPA levels and, as expected, a highly 
signiﬁ  cant improvement in all the clinical variables (see sup-
plementary ﬁ  gures 1 and 2 and supplementary table 1). ACPA 
positivity was found in 65.3% at the end of the follow-up ver-
sus 72.7% at baseline (p=0.001), RF-IgM positivity was seen in 
31.4%   versus 67.8% (p<0.0001) and RF-IgA positivity was seen 
in 16.5%   versus 37.2% (p<0.0001). 
  The variables that arose as signiﬁ  cant predictors of EULAR 
remission were male sex (OR 2.5 (Conﬁ  dence Intervals (CI): 
1.1–5.9))   and ‘having at onset an ESR<35 mm/h’ (OR 2.4 (CI: 
2.2–5.1)). 
  Patients that did not reach ACR remission presented a lon-
ger disease duration at onset (6.4±3.6 months) with respect 
to patients that had reached ACR remission (3.8±2.4 months) 
(p<0.0001) (  table 2  ). The only variable that arose a signiﬁ  cant 
predictor of ACR remission was ‘having VERA disease’ (OR 5.3 
(CI: 2.1–13.0)). 
  Patients with erosions at baseline (28.1%) presented a lon-
ger disease duration (7.1±3.0 months), with respect to patients 
without erosions at diagnosis (5.2±3.4 months) (p=0.005) and 
a higher (though not statistically different) ESR, DAS, HAQ, 
RF-IgM and RF-IgA at onset (  table 3  ).   
  While erosions were present in a similar percentage of patients 
that would reach EULAR remission (26.8%) and of patients 
that would not (29.2%), radiological damage was less frequent 
in patients that would reach ACR remission (16.7%) than in 
patients that would not (31.9%) (  table 2  ). 
  Multivariate analysis demonstrated that the only independent 
predictor of erosiveness at baseline was ‘not having a VERA 
  disease’ (OR 3.9 (CI: 1.5–10.7)). 
  After 12 months, 14 patients (11.6%) became erosive, 13 patients 
(10.7%) presented a worsening of at least 1 point of Sharp and/or 
Larsen score, while 73 patients (60.3%) were still not erosive. 
  The percentage of patients erosive at the end of the follow-up 
was strikingly different in the VERA subset (13 patients (27.1%)) 
versus the non-VERA subset (35 patients (45.4%)), (p=0.005). 
Multivariate analysis demonstrated that the only independent 
predictor of erosiveness at month 12 was ‘not having a VERA 
disease’ (OR 2.4 (CI: 1.1–5.6)). 
  Considering the group of patients that presented a progression 
of the Sharp erosion score, seven patients progressed 1 point, 
three patients 2 points and one patient 4 points. Considering the 
 Table  1        Baseline and 12-month follow-up clinical and biological characteristics of patients reaching DAS remission and not reaching remission at 
follow-up  
 Characteristics 
 Baseline  characteristics 
of patients achieving DAS 
remission (56 patients) 
  Baseline characteristics of 
patients not achieving DAS 
remission (65 patients) 
  Follow-up characteristics of 
patients achieving DAS remission 
(56 patients) 
  Follow-up characteristics of 
patients not achieving DAS 
remission (65 patients) 
Age, years 52.1±15.1 55.0±11.4 – –
Sex, no. F (%) 38 (67.9%) 54 (83.1%)* – –
Disease duration, months 5.6±3.5 5.9±3.5 – –
VERA, n (%) 21 (37.5%) 23 (35.4%) – –
ACPA, U/ml 81.6±133.7 60.6±45.0 45.7±39.8 43.5±38.4
ACPA+, n (%) 47 (83.9%) 41 (63.1%) 38 (69.1%) 41 (63.1%)
RF-IgM, U/ml 94.6±115.2 92.2±136.3 38.9±73.1 34.2±47.7
RF-IgM+, n (%) 38 (67.9%) 44 (67.7%) 17 (30.6%) 21 (32.3%)
RF-IgA, U/ml 165.1±170.1 179.5±249.1 58.3±114.4 33.8±59.7
RF-IgA+, n (%) 23 (41.1%) 22 (33.8%) 11 (20.0%) 9 (14.1%)
ESR, mm/ I° h  31.6±25.0 42.0±24.0* 9.8±6.2 20.8±16.7†
CRP, mg/litre 19.7±26.6 24.3±32.3 2.6±3.6 5.6±7.8†
DAS44 3.0±0.8 3.6±0.7* 1.0±0.4 2.2±0.8†
HAQ-DI 1.1±0.7 1.4±0.7* 0.2±0.2 0.6±0.6†
Erosives 15 (26.8%) 19 (29.2%) 21 (37.5%) 27 (41.5%)
Sharp erosion score 2.4±2.5 2.5±2.2 2.4±2.5 2.5±2.1
Larsen score 3.8±2.4 4.3±3.3 3.6±2.7 4.2±3.0
      Characteristics at baseline and after 12 months of patients reaching DAS remission or not reaching DAS remission after 12 months of follow-up. Values are mean±SD. 
  *p<0.05 between baseline characteristics of patients achieving and not achieving DAS remission. 
  †p<0.05 between 12-month follow-up characteristics of patients achieving and not achieving DAS remission. 
  ACPA, anti-cyclic citrullinated peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire 
Disability Index; RF, rheumatoid factor; VERA, very early rheumatoid arthritis.     
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Larsen’s score, four patients presented a worsening of 1 point, 
four patients of 2 points, two patients of 4 points and one patient 
of 5 points.   
  DISCUSSION 
  The goal of our study was to ﬁ  nd predictors of remission and 
radiographic progression in a cohort of patients that followed a 
therapeutic protocol aiming at remission, in a real world tight-
control setting. Our data show that an aggressive therapeutic 
approach can lead to a major response in a high percentage of 
patients, and more importantly that an ACR remission can be a 
realistic clinical outcome in clinical practice. 
  Other clear-cut messages arose: ﬁ  rst, the major determinant 
of an ACR clinical remission is VERA; second, the major risk 
factor for being erosive at onset is being a ‘no VERA patient’; 
third, the erosivity after 12 months under a strict and aggres-
sive therapeutic protocol depends on a major risk factor, being 
or not in VERA at the point of diagnosis. Therefore all the data 
lead to the clinically relevant issue of early diagnosis and early 
therapeutic intervention within the window of opportunity of 
3 months.  7     15     16   Also, the effect of a later diagnosis did not disap-
pear when an aggressive treatment strategy was applied.  7   
  Unfortunately, despite aiming at remission, and despite lead-
ing to DAS remission in a high percentage of patients and to 
 Table  2        Baseline and 12-month follow-up clinical and biological characteristics of patients reaching ACR remission or not reaching remission at 
follow-up  
 Characteristics 
 Baseline  characteristics 
of patients achieving ACR 
remission (30 patients) 
  Baseline characteristics of 
patients not achieving ACR 
remission (91 patients) 
  Follow-up characteristics of 
patients achieving ACR remission 
(30 patients) 
  Follow-up characteristics of 
patients not achieving ACR 
remission (91 patients) 
Age, years 55.0±13.3 53.2±13.3 – –
Sex, no. F (%) 20 (66.7%) 72 (79.1%) – –
Disease duration, months 3.8±2.4 6.4±3.6* – –
VERA, n (%) 19 (63.3%) 25 (27.5%)* – –
ACPA, U/ml 105.5±175.1 59.1±48.1 61.2±45.2 39.8±35.8
ACPA+, n (%) 20 (66.7%) 68 (74.7%) 18 (62.1%) 61 (67.0%)
RF-IgM, U/ml 55.0±71.2 105.5±138.1 33.7±73.4 37.2±56.7
RF-IgM+, n (%) 19 (63.3%) 63 (69.2%) 7 (24.1%) 31 (34.1%)
RF-IgA, U/ml 130.2±121.0 188.8±237.6 41.2±54.3 48.9±14.8
RF-IgA+, n (%) 13 (43.3%) 32 (37.6%) 8 (27.6%) 12 (13.3%)
ESR, mm/ I° h 34.7±24.3 38.0±24.3 10.3±7.3 17.5±15.3†
CRP, mg/litre 19.8±23.7 22.9±31.5 2.6±5.4 4.8±6.6†
DAS44 3.2±0.7 3.4±0.9 0.8±0.3 2.0±0.8†
HAQ-DI 1.0±0.6 1.3±0.8 0.1±0.2 0.5±0.5†
Erosives 5 (16.7%) 29 (31.9%) 9 (30.0%) 39 (42.9%)
Sharp erosion score 1.8±0.8 2.6±2.5 1.6±0.7 2.7±2.5
Larsen score 3.2±1.8 4.2±3.0 2.7±1.7 4.2±3.0
      Characteristics at baseline and after 12 months of patients reaching ACR remission or not reaching ACR remission after 12 months of follow-up. The values are indicated as the 
mean±SD. 
  *p<0.05 between baseline characteristics of patients achieving and not achieving ACR remission. 
  †p<0.05 between 12-month characteristics of patients achieving and not achieving ACR remission. 
  ACR, American College of Rheumatology; ACPA, anti-cyclic citrullinated peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; 
HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor; VERA, very early rheumatoid arthritis.     
 Table  3        Baseline and 12-month follow-up clinical and biological characteristics of patients with and without erosions at diagnosis   
 Characteristics 
  Baseline characteristics of 
erosive patients at diagnosis 
(34 patients) 
  Baseline characteristics of 
not erosive patients at diagnosis 
(87 patients) 
  Follow-up characteristics of 
erosive patients at diagnosis 
(34 patients) 
  Follow-up characteristics of 
not erosive patients at 
diagnosis (87 patients) 
Age, years 57.7±10.6 2.1±13.9 – –
Disease duration, months 7.1±3.0 5.2±3.4* – –
VERA, n (%) 6 (17.6%) 28 (32.2%)* – –
ACPA, U/ml 60.6±57.1 74.1±108.2 39.3±38.4 46.7±39.1
ACPA+, n (%) 27 (79.4%) 61 (70.1%) 22 (66.7%) 57 (65.5%)
RF-IgM, U/ml 122.4±158.2 79.3±107.6 52.9±76.7 29.4±51.2
RF-IgM+, n (%) 25 (73.5%) 57 (65.5%) 14 (42.4%) 24 (27.6%)
RF-IgA, U/ml 186.6±230.9 164.0±203.8 40.9±67.6 49.8±104.8
RF-IgA+, n (%) 16 (47.1%) 29 (33.3%) 5 (15.2%) 15 (7.4%)
ESR, mm/ I° h 41.5±25.0 35.5±24.6 20.1±19.2 14.0±11.1†
CRP, mg/litre (T=0) 27.4±33.7 20.1±27.9 4.8±9.4 4.0±4.8
DAS44 3.5±0.9 3.2±0.8 1.8±0.8 1.6±0.9
HAQ-DI (T=0) 1.3±0.8 1.2±0.7 0.5±0.6 0.3±0.5
DAS remission – – 15 (44.1%) 41 (47.1%)
HAQ remission – – 22 (64.7%) 69 (79.3%)
ACR remission – – 9 (26.5%) 34 (39.1%)
      Clinical and biological values of variables in patients that were erosive or not erosive at baseline. The values are indicated as the mean±SD. 
  *p<0.05 between baseline characteristics of patients with and without erosion at diagnosis. 
  †p<0.05 between 12-month characteristics of patients with and without erosion at diagnosis. 
  ACR, American College of Rheumatology; ACPA, anti-cyclic citrullinated peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; 
HAQ-DI, Health Assessment Questionnaire Disability Index; RF, rheumatoid factor; VERA, very early rheumatoid arthritis.     
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low disease activity the majority of our cohort, we still had 
11.6% of patients becoming erosive, as already reported.  17     18   
The radiological progression was small in our cohort, and deﬁ  -
nitely hardly clinically signiﬁ  cant. In a recent study, an initial 
combination of MTX and adalimumab compared to an initial 
monotherapy with MTX allowed a faster control of disease 
activity but did not increase the number of patients for whom 
anti-TNFα treatment was not needed after 12 weeks nor a bet-
ter subsequent clinical or radiological outcome than a 3-month 
delayed initiation of anti-TNF in patients with still active disease 
despite MTX.  19   Of interest, DAS remission was seen more often 
in the arm receiving MTX ﬁ  rst than in the combination treat-
ment since the beginning. About 50% of the patients progressed 
in both arms, but progression was quite minimal. 
  Summarising all the studies from the literature, indirect data 
suggest a clear-cut role of the 3-month symptom duration as 
a possible window of opportunity.  20   Our study provides pro-
spective data suggesting that VERA represents the ideal target 
for stopping the erosive course and leading the patient into 
remission. In this setting even an aggressive protocol, used 
beyond the window of opportunity, cannot be used to fully 
avoid progression, even though the radiological progression is 
minimal. 
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